PULSE BIOSCIENCES, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Pulse Biosciences raised $46.8M net in Q2 2026 via ATM (with ~$13M from insiders, $33.8M outside), plus $10.7M net post-quarter and $1.8M from warrant exercise, bringing cash to $101.6M as of June 30, 2026. The company surpassed 82 evaluable patients (halfway) in NANOPULSE-AF pivotal study, increased enrollment target by 19 patients to 164 due to protocol amendment, and reaffirmed early Q4 2026 completion (3 months ahead of original plan). Q2 revenue was $434K; GAAP net loss was $24.7M on $25.7M expenses; non-GAAP net loss $19.4M. Company placed new $75M ATM and maintains $125M shelf registration.
Why this rating
Strong capital raise ($57.5M gross) and clinical momentum significant at $266M market cap (21.6% dilution), but pre-revenue biotech with expanding burn ($18.7M operating cash outflow Q2) means financing is essential, not exceptional. AF trial acceleration is positive but binary regulatory risk remains.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.